Which has better valuation & earnings, ADAG or LXRX?

Adagene has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 24.54 -$17.61M N/A N/A Lexicon Pharmaceuticals $49.80M 16.26 -$50.34M -$0.15 N/A

Which has higher earnings and valuation, ADAG or IMMX?

Adagene has higher revenue and earnings than Immix Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 24.54 -$17.61M N/A N/A Immix Biopharma N/A N/A -$29.44M -$0.88 N/A

Is ADAG or IMMX more profitable?

Adagene's return on equity of 0.00% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Immix Biopharma N/A -38.44% -34.72%

Which has better earnings and valuation, AVTX or ADAG?

Adagene has higher revenue and earnings than Avalo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalo Therapeutics $60K 13,398.56 -$78.26M -$4.37 N/A Adagene $7.67M 24.54 -$17.61M N/A N/A

Is AVTX or ADAG more profitable?

Adagene's return on equity of 0.00% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -58.03% -48.22% Adagene N/A N/A N/A

Which has stronger earnings and valuation, FDMT or ADAG?

Adagene has lower revenue, but higher earnings than 4D Molecular Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 4D Molecular Therapeutics $85.21M 8.86 -$140.11M -$2.63 N/A Adagene $7.67M 24.54 -$17.61M N/A N/A

Which has better valuation & earnings, GERN or ADAG?

Adagene has lower revenue, but higher earnings than Geron. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Geron $204.56M 3.77 -$83.50M -$0.11 N/A Adagene $7.67M 24.54 -$17.61M N/A N/A

Is GERN or ADAG more profitable?

Adagene has a net margin of 0.00% compared to Geron's net margin of -34.17%. Adagene's return on equity of 0.00% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Geron -34.17% -24.48% -10.30% Adagene N/A N/A N/A

Adagene (ADAG) Competitors

$2.85 -0.08 (-2.73%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.85 +0.00 (+0.07%)

As of 10/2/2026 07:30 PM Eastern

Compare

ADAG vs. LXRX, IMMX, AVTX, FDMT, and GERN

Should you buy Adagene stock or one of its competitors? Adagene's main competitors and comparable companies include Lexicon Pharmaceuticals (LXRX), Immix Biopharma (IMMX), Avalo Therapeutics (AVTX), 4D Molecular Therapeutics (FDMT), and Geron (GERN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Adagene compare to Lexicon Pharmaceuticals?

Adagene (NASDAQ:ADAG) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Adagene has higher earnings, but lower revenue than Lexicon Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	24.54	-$17.61M	N/A	N/A
Lexicon Pharmaceuticals	$49.80M	16.26	-$50.34M	-$0.15	N/A

In the previous week, Lexicon Pharmaceuticals had 19 more articles in the media than Adagene. MarketBeat recorded 19 mentions for Lexicon Pharmaceuticals and 0 mentions for Adagene. Adagene's average media sentiment score of 0.45 beat Lexicon Pharmaceuticals' score of 0.39 indicating that Adagene is being referred to more favorably in the media.

Company	Overall Sentiment
Adagene	Neutral
Lexicon Pharmaceuticals	Neutral

Adagene has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

Adagene has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Adagene's return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

9.5% of Adagene shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Adagene presently has a consensus price target of $8.67, suggesting a potential upside of 204.09%. Lexicon Pharmaceuticals has a consensus price target of $5.70, suggesting a potential upside of 213.19%. Given Lexicon Pharmaceuticals' higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Adagene beats Lexicon Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Adagene compare to Immix Biopharma?

Adagene (NASDAQ:ADAG) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

9.5% of Adagene shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Immix Biopharma had 24 more articles in the media than Adagene. MarketBeat recorded 24 mentions for Immix Biopharma and 0 mentions for Adagene. Adagene's average media sentiment score of 0.45 beat Immix Biopharma's score of 0.39 indicating that Adagene is being referred to more favorably in the media.

Company	Overall Sentiment
Adagene	Neutral
Immix Biopharma	Neutral

Adagene has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Adagene presently has a consensus target price of $8.67, suggesting a potential upside of 204.09%. Immix Biopharma has a consensus target price of $24.14, suggesting a potential upside of 149.41%. Given Adagene's stronger consensus rating and higher probable upside, research analysts plainly believe Adagene is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Adagene's return on equity of 0.00% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Immix Biopharma	N/A	-38.44%	-34.72%

Adagene has higher revenue and earnings than Immix Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	24.54	-$17.61M	N/A	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

Summary

Adagene beats Immix Biopharma on 9 of the 13 factors compared between the two stocks.

How does Adagene compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Avalo Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Adagene has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Adagene has higher revenue and earnings than Avalo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	13,398.56	-$78.26M	-$4.37	N/A
Adagene	$7.67M	24.54	-$17.61M	N/A	N/A

Adagene's return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Adagene	N/A	N/A	N/A

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 21.2% of Adagene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Avalo Therapeutics presently has a consensus target price of $45.10, indicating a potential upside of 200.87%. Adagene has a consensus target price of $8.67, indicating a potential upside of 204.09%. Given Adagene's higher probable upside, analysts plainly believe Adagene is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Adagene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Avalo Therapeutics had 3 more articles in the media than Adagene. MarketBeat recorded 3 mentions for Avalo Therapeutics and 0 mentions for Adagene. Adagene's average media sentiment score of 0.45 beat Avalo Therapeutics' score of 0.29 indicating that Adagene is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalo Therapeutics	Neutral
Adagene	Neutral

Summary

Adagene beats Avalo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Adagene compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Adagene has lower revenue, but higher earnings than 4D Molecular Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.86	-$140.11M	-$2.63	N/A
Adagene	$7.67M	24.54	-$17.61M	N/A	N/A

Adagene has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. Adagene's return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Adagene	N/A	N/A	N/A

4D Molecular Therapeutics currently has a consensus target price of $29.00, suggesting a potential upside of 112.14%. Adagene has a consensus target price of $8.67, suggesting a potential upside of 204.09%. Given Adagene's higher possible upside, analysts clearly believe Adagene is more favorable than 4D Molecular Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Adagene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

4D Molecular Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the broader market. Comparatively, Adagene has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, 4D Molecular Therapeutics had 5 more articles in the media than Adagene. MarketBeat recorded 5 mentions for 4D Molecular Therapeutics and 0 mentions for Adagene. 4D Molecular Therapeutics' average media sentiment score of 0.55 beat Adagene's score of 0.45 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
4D Molecular Therapeutics	Positive
Adagene	Neutral

Summary

4D Molecular Therapeutics and Adagene tied by winning 7 of the 14 factors compared between the two stocks.

How does Adagene compare to Geron?

Geron (NASDAQ:GERN) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Adagene has lower revenue, but higher earnings than Geron.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$204.56M	3.77	-$83.50M	-$0.11	N/A
Adagene	$7.67M	24.54	-$17.61M	N/A	N/A

Geron has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Adagene has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

In the previous week, Geron had 1 more articles in the media than Adagene. MarketBeat recorded 1 mentions for Geron and 0 mentions for Adagene. Geron's average media sentiment score of 1.54 beat Adagene's score of 0.45 indicating that Geron is being referred to more favorably in the media.

Company	Overall Sentiment
Geron	Very Positive
Adagene	Neutral

Geron currently has a consensus price target of $4.00, indicating a potential upside of 233.33%. Adagene has a consensus price target of $8.67, indicating a potential upside of 204.09%. Given Geron's higher possible upside, research analysts clearly believe Geron is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Adagene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Adagene has a net margin of 0.00% compared to Geron's net margin of -34.17%. Adagene's return on equity of 0.00% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Adagene	N/A	N/A	N/A

73.7% of Geron shares are owned by institutional investors. Comparatively, 9.5% of Adagene shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Adagene beats Geron on 9 of the 15 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADAG vs. The Competition

Export

Metric	Adagene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$188.25M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	N/A	13.06	275.66	26.04
Price / Sales	24.54	1,292.11	608.92	91.72
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	3.80	16.63	10.93	6.31
Net Income	-$17.61M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-2.73%	-2.99%	-2.00%	-1.66%
1 Month Performance	-20.39%	-10.81%	-6.19%	-4.68%
1 Year Performance	43.94%	19.19%	8.03%	1.57%

Adagene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADAG Adagene	3.4329 of 5 stars	$2.85 -2.7%	$8.67 +204.1%	+43.9%	$188.25M	$7.67M	N/A	128	Gap Up
LXRX Lexicon Pharmaceuticals	1.9246 of 5 stars	$1.88 -1.1%	$5.70 +203.2%	+29.1%	$845.42M	$49.80M	N/A	81
IMMX Immix Biopharma	3.1069 of 5 stars	$10.54 -8.1%	$24.14 +129.1%	+369.9%	$820.56M	N/A	N/A	21	Analyst Forecast High Trading Volume
AVTX Avalo Therapeutics	2.423 of 5 stars	$15.58 +3.3%	$45.10 +189.5%	+11.9%	$808.74M	$60K	N/A	33
FDMT 4D Molecular Therapeutics	2.8323 of 5 stars	$14.49 -0.5%	$29.00 +100.1%	+59.9%	$804.36M	$85.21M	N/A	196	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADAG) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adagene (ADAG) Competitors

ADAG vs. LXRX, IMMX, AVTX, FDMT, and GERN

How does Adagene compare to Lexicon Pharmaceuticals?

Summary

How does Adagene compare to Immix Biopharma?

Summary

How does Adagene compare to Avalo Therapeutics?

Summary

How does Adagene compare to 4D Molecular Therapeutics?

Summary

How does Adagene compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adagene (ADAG) Competitors

ADAG vs. LXRX, IMMX, AVTX, FDMT, and GERN

How does Adagene compare to Lexicon Pharmaceuticals?

Which has better valuation & earnings, ADAG or LXRX?

Does the media prefer ADAG or LXRX?

Which has more volatility and risk, ADAG or LXRX?

Is ADAG or LXRX more profitable?

Do institutionals & insiders hold more shares of ADAG or LXRX?

Do analysts rate ADAG or LXRX?

Summary

How does Adagene compare to Immix Biopharma?

Do insiders & institutionals hold more shares of ADAG or IMMX?

Does the media prefer ADAG or IMMX?

Which has more risk & volatility, ADAG or IMMX?

Do analysts rate ADAG or IMMX?

Is ADAG or IMMX more profitable?

Which has higher earnings and valuation, ADAG or IMMX?

Summary

How does Adagene compare to Avalo Therapeutics?

Which has more volatility & risk, AVTX or ADAG?

Which has better earnings and valuation, AVTX or ADAG?

Is AVTX or ADAG more profitable?

Do institutionals & insiders believe in AVTX or ADAG?

Do analysts prefer AVTX or ADAG?

Does the media favor AVTX or ADAG?

Summary

How does Adagene compare to 4D Molecular Therapeutics?

Which has stronger earnings and valuation, FDMT or ADAG?

Is FDMT or ADAG more profitable?

Do analysts recommend FDMT or ADAG?

Which has more risk & volatility, FDMT or ADAG?

Do institutionals and insiders have more ownership in FDMT or ADAG?

Does the media favor FDMT or ADAG?

Summary

How does Adagene compare to Geron?

Which has better valuation & earnings, GERN or ADAG?

Which has more volatility and risk, GERN or ADAG?

Does the media favor GERN or ADAG?

Do analysts rate GERN or ADAG?

Is GERN or ADAG more profitable?

Do institutionals & insiders have more ownership in GERN or ADAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools